Lung cancer at ASCO 2027
Jun 4–8, 2027 Chicago, IL ~44k attendees Website
28 organizations at ASCO 2027 present work in lung cancer: 21 drug developers, 6 diagnostics, technology and service companies and 1 advocacy group, society, cancer center, publisher or agency. 28 of them have their own page in this guide. As of Oct 8, 2026.
Showing 1–20 of 28 organizations
| Organization | ASCO 2027 Attendance |
|---|---|
Akeso Zhongshan City, China | |
Chinese antibody drugmaker with bispecific immunotherapies, including the PD-1/VEGF antibody ivonescimab for lung cancer. | Booth Exhibiting at Booth 37147 |
Amgen Thousand Oaks, CA | |
Biotechnology drugmaker with cancer medicines for lung, blood and colorectal cancers, including targeted therapies and bispecific T-cell engagers. | Booth Exhibiting at Booth 22025 |
Amoy Diagnostics Xiamen, China | |
Chinese maker of PCR and sequencing kits that detect tumor gene mutations, including companion diagnostics widely used in lung cancer. | Booth Exhibiting at Booth 22114 |
AstraZeneca Cambridge, UK | |
Global drugmaker with cancer medicines across lung, breast, blood and other cancers, including targeted therapies, immunotherapy and ADCs. | Booth Exhibiting at Booth 19029 |
Biodesix Louisville, CO | |
Diagnostics company with blood-based lung cancer tests, plus development services for biopharma diagnostic and drug programs. | Booth Exhibiting at Booth 30099 |
Boehringer Ingelheim Ingelheim, Germany | |
Family-owned German drugmaker whose oncology work centers on lung cancer, including the HER2 inhibitor zongertinib, plus other solid tumors. | Booth Exhibiting at Booth 27109 |
Burning Rock Dx Guangzhou, China | |
Chinese NGS cancer testing company offering tissue and liquid biopsy assays, companion diagnostic development and a multi-cancer early detection test. | Booth Exhibiting at Booth 14157 |
Chugai Pharmaceutical Chuo-ku, Japan | |
Japanese drugmaker in the Roche group, known for antibody engineering; its cancer medicines include alectinib for ALK-positive lung cancer. | Booth Exhibiting at Booth 10072 |
Daiichi Sankyo Tokyo, Japan | |
Japanese drugmaker known for antibody-drug conjugates, including trastuzumab deruxtecan (Enhertu) and datopotamab deruxtecan, for breast, lung and gastric cancers. | Booth Exhibiting at Booth 27073 |
Eli Lilly Indianapolis, IN | |
Global drugmaker whose cancer medicines include abemaciclib for breast cancer, selpercatinib for RET-driven cancers and pirtobrutinib for blood cancers. | Booth Exhibiting at Booth 19079 |
EMD Serono (Merck KGaA) Boston, MA | |
Healthcare business of Germany's Merck KGaA, with EMD Serono's cancer medicines for colorectal, bladder and lung cancer and SpringWorks' rare tumor drugs. | Booth Exhibiting at Booth 23093 |
Genentech South San Francisco, CA | |
Roche company and biotechnology drugmaker with cancer medicines for breast, lung and blood cancers, including atezolizumab and bispecific antibodies. | Booth Exhibiting at Booth 19001 |
Henlius Shanghai, China | |
Shanghai biopharma making biosimilars and novel antibodies, including the PD-1 antibody serplulimab and a trastuzumab biosimilar. | Booth Exhibiting at Booth IH03 |
Global professional network for lung cancer research and care that runs the World Conference on Lung Cancer and regional meetings. | Booth Exhibiting at Booth 14033 |
Jazz Pharmaceuticals Dublin, Ireland | |
Rare disease and oncology drugmaker with medicines for leukemia, small cell lung cancer and HER2-positive biliary tract cancer. | Booth Exhibiting at Booth 34095 |
Johnson & Johnson New Brunswick, NJ | |
Global healthcare company whose Innovative Medicine unit markets cancer drugs for myeloma, lung, prostate and bladder cancers, including daratumumab and amivantamab. | Booth Exhibiting at Booth 15033 |
Merck Rahway, NJ | |
Global drugmaker behind the PD-1 antibody pembrolizumab (Keytruda), with cancer trials in over 30 tumor types and a growing ADC pipeline. | Booth Exhibiting at Booth 14013 |
Novocure Portsmouth, NH | |
Maker of Tumor Treating Fields, a wearable device therapy approved for glioblastoma, mesothelioma and lung cancer, also studied in pancreatic cancer. | Booth Exhibiting at Booth 30131 |
Nuvation Bio New York, NY | |
Oncology drugmaker marketing taletrectinib for ROS1-positive lung cancer and developing therapies for brain tumors. | Booth Exhibiting at Booth 31155 |
OncoHost Cary, NC | |
Blood proteomics test, PROphet, that uses machine learning to help guide first-line immunotherapy decisions in non-small cell lung cancer. | Booth Exhibiting at Booth 14097 |
Instantly find 20 buyers in lung cancer
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASCO 2027 by
Organization type
Focus
- Clinical trials 58
- Biomarkers and genomics 44
- AI and data 38
- Blood cancers 36
- Lung cancer 28
- Genitourinary cancers 24
- Gastrointestinal cancers 21
- Breast cancer 18
- Immunotherapy 17
- Imaging and radiation 17
- Patient support and survivorship 14
- Antibody-drug conjugates 9
- Cell and gene therapy 8
- Melanoma and skin cancers 7
- Gynecologic cancers 6
Exhibit hall
Everyone
Not affiliated with the American Society of Clinical Oncology. Organization details are derived from ASCO’s published exhibitor list and each exhibitor’s own profile and website. Submit a correction